Recently, Jiangsu Huanghe Pharmaceutical Co., Ltd., a member enterprise of Wanbang Biopharma under Fosun Pharma, received the Notice on Approval of Supplementary Drug Application for Loratadine Tablets (10 mg) from NMPA because the drug has passed the consistency evaluation of quality and efficacy of generic drugs.

According to WHO, 20% ~ 30% of the general population worldwide suffers from allergic symptoms. In China, 270 million people are afflicted with allergies of different severity, including common allergic symptoms such as skin redness and swelling, pruritus, macules and respiratory diseases.

Antihistamines are widely used anti-allergic drugs in clinical practice. They are often used for desensitization of allergic diseases and also play a very important role in the treatment of urticaria, allergic rhinitis and allergic asthma.

Loratadine, a second-generation antihistamine, has long-acting, non-sedative and non-anticholinergic effects, selective anti-peripheral histamine H1 receptors and no drowsiness side effects in the therapeutic range, and is indicated for lacrimation, sneezing, allergic rhinitis, acute and chronic urticaria, and other allergic skin diseases.

As a classic anti-allergic drug, Minlike^® (Loratadine Tablets) of Jiangsu Huanghe Pharmaceutical Co., Ltd. has passed the generics consistency, which will provide an option for more allergic people, and help improve the product's competitiveness, enhance the product's market position and bring new market opportunities!